Market Overview

Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey

Share:
Related BIIB
Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected
A New Active Alternative For Equity Exposure
Jeff Ubben Buys –, Sells – in –st Quarter (GuruFocus)

In a report published Friday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB).

In the report, Urist noted, “Our AlphaWise survey of 121 neurologists in the US and Europe (performed in the month prior to Tecfidera approval) supports a strong launch, $4B+ in sales potential for Biogen's Tecfidera, and our Overweight rating. Roughly half of patients are expected to be on oral therapies within 4-6 years. This implies $4B+ in global sales assuming Tecfidera gains at least 50-60% of the oral segment, which is at the high end of long-term consensus of $3.4-4B. Of note, ABCR share declines from ~80% to ~30% while the high-efficacy segment gains 15% share over this period.”

Biogen Idec closed on Thursday at $217.30.

Latest Ratings for BIIB

DateFirmActionFromTo
Mar 2017Leerink SwannDowngradesOutperformMarket Perform
Mar 2017Morgan StanleyDowngradesOverweightEqual-Weight
Feb 2017CitigroupUpgradesNeutralBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!